Thus, physicians should still consider the potential risks of acute nephritis and renal failure in administering GLP‐1 RAs, particularly for individuals with uncontrolled T2D, polyuria, polydipsia, or those prone to volume depletion.35, 37, 38, 39. This evidence concerns the gene GLP1R and acute kidney injury.